Pegcetacoplan for geographic atrophy receives negative opinion from European committee

The Committee for Medicinal Products for Human Use of the European Medicines Agency issued a negative opinion on a marketing authorization application for pegcetacoplan, according to an Apellis Pharmaceuticals press release.
The opinion was expected based on a negative trend vote after an oral explanation meeting in December 2023, the release said.
The application for intravitreal pegcetacoplan for the treatment of geographic atrophy secondary to age-related macular degeneration was based on the phase 3 OAKS and DERBY studies, which compared the efficacy and safety of pegcetacoplan with sham

Leave a Comment

Your email address will not be published. Required fields are marked *

Shopping Cart